-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Angiosin-converting enzyme 2 (ACE2) is a key target of the renin-angiosin-aldosterone system (RAAS) and a "gateway" for the invasion of cells by severe acute respiratory syndrome coronavirus 2 (SARS-cov-2).
Recently, researchers examined the effects of stopping or continuing to receive angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II blockers (ARBs) on the prognosis of 30-day neocycline pneumonia in patients with COVID-19 with high blood pressure.
involved 659 mild and moderate COVID-19 hospitalized patients who took ACEIs or ARBs before being hospitalized, 334 of whom stopped ACEIs or ARBs and 325 continued ACEIs or ARBs treatment.
of the study was the number of days to survive and be discharged from the hospital within 30 days.
secondary endpoints include death, cardiovascular death and COVID-19 progression.
age was 55.1 years, 14.7 per cent were patients aged 70 and over, 40.4 per cent were women, and all patients completed the trial.
the average time from the on-the-look symptoms to the hospital was 6 days.
at baseline, the proportion of patients with oxygen saturation below 94% was 27.2%, 57.1% were assessed as mild and 42.9% moderate when admitted to hospital.
the number of days of survival-discharge in patients in the discontinued ACEIs or ARBs treatment group was not significantly different from that in the ongoing treatment group (21.9 vs 22.9 days, OR=0.95).
between groups (2.7% vs. continued treatment group 2.8%; OR: 0.97), cardiovascular death (0.6% vs. 0.3%; OR: 1.95) or COVID-19 progression (38.3% vs 32.3%; OR: 1.30) risk was equal.
common adverse events are respiratory failure, shock, acute myocardial infarction, new or worsening heart failure, and acute renal failure.
For patients with mild to moderate neocytic pneumonia who are taking angiosin conversion enzyme inhibitor (ACEIs) or angiosin II blocker (ARBs), the above-mentioned patients are not supported to stop anti-stress medication due to neocycline pneumonia factors.
